Abstract
This report examines plasma amyloid β proteins Aβ40 and Aβ42 and apolipoprotein E (apoE) levels and their relationships with age in non-demented older adults with (N = 32) or without the apoE-ε4 allele (N = 94). Aβ levels did not differ between the groups whereas the ε4 allele was associated with a significant reduction in plasma apoE. In subjects with the ε4 allele, increasing age was associated with significant reduction in plasma Aβ40. Subjects without the ε4 allele showed a significant positive correlation between Aβ40 and Aβ42 levels. There was also a significant correlation between plasma Aβ40 and apoE levels in all subjects.
REFERENCES
Strittmatter, W. J., and Roses, A. D. 1995. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci USA. 92:4725-4727.
Beffert, U., and Poirier, J. 1996. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann NY Acad Sci. 777:166-74.
Ohm, T. G., Kirca, M., Bohl, J., Scharnagl, H. Gross, W. and Marz, W. 1995. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience. 66:583-587.
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinisto, L., Halonen, P., and Kontula, K. 1995. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333:1242-1247.
Sparks, D. L., Scheff, S. W., Liu, H., Landers, T., Danner, F., Coyne, C. M., and Hunsaker, J. C. 3rd. 1996. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to comfirmed Alzheimer's disease patients. J. Neurol. Sci. 138:97-104.
Landen, M., Thorsell, A., Wallin, A., and Blennow, K. 1996. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 61:352-356.
Morris, C. M., Massey, H. M., Benjamin, R., Leake, A., Broadbent, C., Griffiths, M., Lamb, H., Brown, A., Ince, P. G., Tyrer, S., Thompson, P., McKeith, I. G., Edwardson, J. A., Perry, R. H., and Perry, E. K. 1996. Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias. J Neural Transm Suppl. 47:205-218.
Benjamin, R., Leake, A., Ince, P. G., Perry, R. H., McKeith, I. G., Edwardson, J. A., and Morris, C. M. 1995. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Neurodegeneration. 1:443-448.
Heinonen, O., Lehtovirta, M., Soininen, H., Helisalmi, S., Mannernaa, A., Sorvari, H., Kosunen, O., Paljarvi, L., Ryynanen, M., and Riekkinen, P. J., Jr. 1995. Alzheimer pathology of patients carrying the apolipoprotein E epsilon 4 allele. Neurobiol Aging. 16:505-513.
Wisniewski, T., Castano, E. M., Golabek, A., Vogel, T., and Frangione, B. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 145:1030-1035.
Strittmatter, W. J., Saunders, A. M., Goedert, M., and Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., and Roses, A. D. 1994. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA. 91:11183-11186.
Bertrand, P., Poirier, J., Oda, T., Finch, C. E., and Pasinetti, G. M. 1995. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res. 33:174-178.
Higgins, G. A., Large, C. H., Rupniak, H. T., and Barnes, J. C. 1997. Apolipoprotein E and Alzheimer's disease: a review of recent studies. Pharmacl Biochem and Behav. 56:675-685.
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., and Zlokovic, B. V. 1997. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem. 69:1995-2004.
Folstein, M. F., Folstein, S. E., and McHugh, P. R. 1975. “Minimental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:189-198.
Kataoka, S., Paidi, M., and Howard, B. V. 1994. Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. 1994. Clin Chem. 40:11-13.
Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., and Wisniewski, H. M. 1998. Increased plasma amyloid beta protein 1–42 levels in Down syndrome. Neurosci Lett. 241:13-16.
Boerwinkle, E., and Utermann, G. 1988. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 42:104-112.
Lehtimäki, T., Pirttilä, T., Mehta, P. D., Wisniewski, H. M., Frey, H., and Nikkari, T. 1995. Apolipoprotein E (apoE) polymorphism and its influence on ApoE levels in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet. 95:39-42.
Maness, L. M., Banks, W. A., Podlisny, M. B., Selkoe, D. J., and Kastin, A. J. 1994. Passage of human amyloid beta-protein 1–40 across the murine blood-brain barrier. Life Sci. 55:1643-1650.
Chen, M., Inestrosa, N. C., Ross, G. S., and Fernandez, H. L. 1995. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 213:96-103.
Mattson, M. P. 1997. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 77:1081-1132.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pomara, N., Shao, B., Wisniewski, T. et al. Decreases in Plasma Aβ1-40 Levels with Aging in Non-Demented Elderly with ApoE-ε4 Allele. Neurochem Res 23, 1563–1566 (1998). https://doi.org/10.1023/A:1020936222286
Issue Date:
DOI: https://doi.org/10.1023/A:1020936222286